# Trending Content OS — Daily Run
**Run Date:** 2026-11-05 | **Niche:** Health & Wellness

---

## 1. Preflight Summary

| Check | Status |
|---|---|
| All configs loaded (7/7) | ✅ |
| `site_niche` / `target_audience` set | ✅ |
| `site_url` | ⚠️ Not configured — self-check skipped, competitor-list fallback used (configs/competitor_list.yaml) |
| Google Trends | ✅ Available via injected SerpAPI pre-fetch (`search_velocity_source: google_trends`) |
| Google News Radar | ✅ Injected — 144 unique headlines across 12 queries |
| `data/deferred_topics.yaml` | No entries with a passed `recheck_on` date |
| `data/run_history.yaml` recurring themes | "Men's Mental Health Month," "wellness trends skepticism," and "FDA recall" clusters have appeared in 3+ consecutive runs → flagged stale/recurring below |

**Decision:** `next_action: run_signal_listener` — proceeding with full pipeline.

---

## 2. Google News Radar Coverage Summary

| Cluster | Disposition | Why |
|---|---|---|
| **FDA recalls (olmesartan BP med, flour/cinnamon, Tractor Wheels, Impella)** | **Rejected — existing** | All already covered 11/01–11/03; today's headlines are continued secondary pickup of the same events, no new casualty count or agency escalation |
| **New recall: compounded eye drops / atorvastatin mix-up / GLP-1s** ([MedShadow](https://medshadow.org/drug-updates-recalls/fda-recalls-and-warnings/atorvastatin-eye-drops-acetaminophen-compounded-glp-1s/)) | **Rejected — unverified** | Single non-tier source, no FDA.gov notice retrieved, breaking-recall exception requires 3+ corroborating sources — not met |
| **Ebola — CDC travel advisory + WHO/UN News vaccine trial expansion** ([WHO](https://www.who.int/news/item/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances), [UN News](https://news.un.org/en/story/2026/11/1168742)) | **Retained** | Convergence across CDC + WHO + UN News, tier-1 institutional sourcing, no prior coverage |
| **Medical study cluster (Stanford Alzheimer's, cannabis/CVD, CT radiation variation, NIH HIV mobile units, AI discharge summaries)** | **Mixed** | Stanford Alzheimer's study retained (direct institutional source); cannabis and CT-radiation studies rejected at Skill 02b — both sourced only to News-Medical with no confirmed primary traceability |
| **Nature journal: potassium-enriched salt substitute study** ([Nature](https://www.nature.com/articles/s44360-026-00216-9)) | **Retained** | Direct primary journal/DOI source — highest-quality sourcing of the day |
| **Clinical trial industry/vendor news (Walmart/Care Access, Signant Health, AJMC costs, Brazil/Canada regulatory, Pfizer pediatric dosing)** | **Rejected — off-category** | Pure industry/business trade coverage, not patient-facing; Pfizer item also flagged as possible stale/recycled story ID |
| **WHO climate-health report (1.6M lives)** ([WHO](https://www.who.int/news/item/04-11-2026-six-climate-and-health-actions-could-save-1.6-million-lives-and-deliver-trillions-in-benefits-each-year)) | **Monitored (P5)** | Legitimate tier-1 source but trend_strength scored below threshold (45.75) — global policy framing, thin US-consumer actionability today |
| **CVS Health pharmacy/insurance split** | **Rejected — off-category** | Pure corporate business news, no direct patient-access angle |
| **Wellness industry fluff (McKinsey $2.7T report, GMA wellness page, school/college wellness centers & fairs, benefits enrollment, Outside Magazine "wellness trends" piece)** | **Rejected — off-category / existing** | Outside Magazine piece duplicates 11/04 coverage; remainder is local/institutional PR noise, not national audience signal |
| **Aflac "Wellness Paradox" survey** | **Rejected — brand safety** | Single-source corporate PR from an insurer with commercial interest in the finding; no independent corroboration |
| **Political health searches (Mitch McConnell, Chris Murphy health status)** | **Rejected — off-category** | Political figure health speculation, excluded per brand safety rules |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-11-05T13:00:00Z"
  run_completed_at: "2026-11-05T13:42:00Z"
  total_signals_reviewed: 153   # 144 Google News Radar + 9 Google Trends keyword clusters
  total_signals_retained: 3
  total_monitored: 1
  total_rejected: 40            # explicitly itemized; remainder of radar = local/duplicate noise, bucketed not individually logged
  google_trends_available: true
  search_velocity_source: "google_trends (estimated for non-seeded topics)"
  rejection_breakdown:
    off_category: 24
    brand_safety: 1
    duplicate: 8
    weak_signal: 3
    unverified_claim: 3
    other: 1
  highest_priority_topic: "WHO/UN confirm two new Ebola vaccine candidates joining DRC clinical trial"
  strongest_signal_source: "who.int (tier-1 institutional, corroborated by UN News + CDC advisory)"
  tools_unavailable: []
  notes: >
    Heavy overlap with the last 7 days' coverage (recalls, Men's Mental Health Month, DST,
    wellness-trends skepticism) meant most of today's radar was duplicate or off-category —
    consistent with a "default is no" editorial posture. Two rising Google Trends queries
    ("dairy vs vegan milk nutrition study," "FDA infant formula nutrition updates") had no
    corroborating News article and were not actionable today; deferred for monitoring if
    news coverage emerges. Men's Mental Health Month and wellness-trends-skepticism themes
    are now flagged recurring (3+ consecutive runs) — risk of staleness, deprioritize unless
    a new data point appears.
```

---

## 4. Skill 02b — Health Claim Verification Gate: Routing Summary

| Topic | Risk Type | Primary Source Found | Gate Result | Notes |
|---|---|---|---|---|
| Ebola vaccine trial (DRC) | clinical_trial | Yes — WHO official release + UN News | **Pass** | Institutional source is the announcement itself |
| Stanford Alzheimer's brain-activity study | medical_study | Yes — Stanford Medicine (own research) | **Pass, mild-overstatement note** | Headline framing ("predict years before memory slips") likely overstates certainty for an early-stage/correlative finding |
| Nature potassium-salt substitute study | medical_study | Yes — direct journal/DOI link | **Pass** | Primary source is the journal article itself |
| Cannabis/cardiovascular risk study | medical_study | No — News-Medical only, no journal/DOI named | **Reject** | Unverifiable: secondary aggregator, no traceable primary source |
| Medicare ExRad CT radiation variation study | medical_study | No — News-Medical only | **Reject** | Same unverifiable-secondary-source issue |
| Compounded eye drops recall | recall | No — single source (MedShadow), no FDA.gov notice | **Reject** | Breaking-recall exception requires 3+ corroborating sources; not met |
| WHO climate-health report | n/a (policy report, not drug/study/recall) | n/a | **Not applicable** | Routed normally through Skill 02/06 |

---

## 5. Final Editorial Priority Board

```yaml
priority_board:
  - priority_level: P1
    publish_timing: immediate
    topic: "Two new Ebola vaccine candidates join active DRC clinical trial"
    primary_entity: "Ebola vaccine trial (DRC)"
    signal_type: clinical_trial
    allowed_category: infectious disease
    trend_strength_score: 63
    opportunity_score: 72
    discover_score: 4
    urgency: today
    confidence: high
    content_status: new
    source_count: 3
    recommended_angle: "Explainer: what adding two vaccine candidates to an active outbreak trial actually means for containment — translate WHO/UN language for a general audience"
    why_now: "WHO and UN News confirmed the trial expansion today (11/05); CDC has concurrent traveler guidance for Ebola-affected areas — first national-audience Ebola signal in recent coverage history"
    primary_headline: "WHO Adds Two New Vaccines to Ebola Outbreak Trial — Here's What That Means"
    next_steps: "Assign full deep-dive brief; confirm no US case risk framing is overstated"
    notes: "⚠️ Clarify vaccines are entering trial stage, not approved/proven — avoid implying outbreak is resolved"

  - priority_level: P2
    publish_timing: short_term
    topic: "Global study: replacing table salt with potassium-enriched salt substitute tied to major cardiovascular health gains"
    primary_entity: "Potassium-enriched salt substitute"
    signal_type: study_or_research
    allowed_category: nutrition and diet science
    trend_strength_score: 52
    opportunity_score: 79
    discover_score: 5
    urgency: this_week
    confidence: medium
    content_status: new
    source_count: 1
    recommended_angle: "Practical evaluative: 'Should you switch to potassium salt?' — translate global population-level modeling into an individual decision framework"
    why_now: "Published directly in Nature (11/04), with direct DOI link — strongest primary sourcing of the day; dovetails with evergreen sodium/heart-health search demand"
    primary_headline: "A New Global Study Says Swapping Your Salt Could Save Millions of Lives — Should You?"
    next_steps: "Full brief; confirm whether findings are modeled/epidemiological vs. interventional before drafting"
    notes: "⚠️ Clarify modeling/observational nature — do not frame as RCT-proven individual outcome"

  - priority_level: P3
    publish_timing: scheduled
    topic: "Stanford study: brain activity patterns may predict Alzheimer's years before memory loss"
    primary_entity: "Alzheimer's disease predictive biomarker"
    signal_type: study_or_research
    allowed_category: aging and longevity
    trend_strength_score: 50
    opportunity_score: 78
    discover_score: 4
    urgency: this_week
    confidence: low
    content_status: new
    source_count: 1
    recommended_angle: "Skeptical/evaluative: what this biomarker research can and can't tell you today — manage expectations on an emotionally loaded topic"
    why_now: "Stanford Medicine published 11/04; no prior coverage, but single-source and uncorroborated — treat as early signal, not breaking news"
    primary_headline: "Can a Brain Scan Predict Alzheimer's Before Symptoms Start? What a New Stanford Study Found"
    next_steps: "Concise brief only; hold for corroboration from a second outlet/journal citation before upgrading priority"
    notes: "⚠️ Confirm cohort size and study design (observational vs. longitudinal); avoid implying diagnostic certainty — low confidence due to single institutional source"

  - priority_level: P5
    publish_timing: monitor
    topic: "WHO: six climate actions could save 1.6 million lives annually"
    primary_entity: "WHO climate and health report"
    signal_type: policy_or_regulatory_change
    allowed_category: environmental health
    trend_strength_score: 46
    opportunity_score: 64
    discover_score: null
    urgency: evergreen
    confidence: medium
    content_status: new
    source_count: 1
    recommended_angle: "Not yet briefed — monitor for secondary coverage or a US-specific policy angle"
    why_now: "Published 11/04 by WHO; globally framed with limited immediate US-consumer actionability"
    primary_headline: null
    next_steps: "Re-check in 3 days for secondary pickup or a domestic policy hook; promote only if trend_strength clears 50"
    notes: "Trend strength (46) fell below the 50 minimum; opportunity score (64) alone insufficient to pass"

summary:
  total_topics: 4
  high_priority_count: 1
  immediate_actions: "Publish Ebola vaccine trial explainer (P1) within 24h; queue potassium-salt brief (P2) for 1–3 day window"
pass_to_next_layer: false
```

---

## 6. Editorial Briefs

### P1 — Ebola Vaccine Trial Expansion (Full Brief)

```yaml
brief:
  primary_headline: "WHO Adds Two New Vaccines to Ebola Outbreak Trial — Here's What That Means"
  alternate_headlines:
    - "What a Trial Expansion Really Tells Us About Ebola Outbreak Response"
    - "Two New Ebola Vaccine Candidates Just Entered a DRC Clinical Trial"
  topic: "Two new Ebola vaccine candidates join active DRC clinical trial"
  primary_entity: "Ebola vaccine trial (DRC)"
  search_intent: "Informational — 'what does this mean,' 'is Ebola a risk to me'"
  angle: "Translate the institutional announcement into a plain-language explainer: what joining a trial means at this outbreak stage, how it differs from approval, and what (if any) relevance it has for US readers."
  why_now: "WHO and UN News jointly confirmed the expansion today; CDC traveler guidance is concurrently active — first fresh Ebola signal in recent run history, strong tier-1 convergence."
  integrity_flags:
    - "⚠️ Integrity note: Vaccine candidates are entering trial, not approved — do not imply efficacy or imminent outbreak resolution."
    - "⚠️ Integrity note: Clarify DRC outbreak status vs. any US risk — avoid fear-based framing given low direct US relevance."
  outline:
    intro: "What just happened: WHO/UN announcement, in plain terms"
    sections:
      - "How vaccine trials add candidates mid-outbreak, and why that's normal"
      - "What's known about outbreak scale and containment so far"
      - "Is there any risk to US travelers or residents? (CDC advisory context)"
    conclusion: "What to watch next: trial timelines, WHO updates"
  key_data_points:
    - "Two new candidate vaccines added to DRC Ebola trial (WHO, 11/05)"
    - "CDC active travel guidance for Ebola-affected areas"
  source_plan:
    - { publisher: "World Health Organization", url: "https://www.who.int/news/item/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances", tier: 1, used_for: "Primary announcement" }
    - { publisher: "UN News", url: "https://news.un.org/en/story/2026/11/1168742", tier: 1, used_for: "Corroboration, trial context" }
    - { publisher: "CDC", url: "https://www.cdc.gov/ebola/situation-summary/returning-travelers.html", tier: 1, used_for: "US traveler guidance" }
  evidence_requirements: "Institutional primary sources sufficient; no additional data needed"
  expert_sources:
    - { type: "Infectious disease epidemiologist", name: "Reference WHO/CDC spokesperson quoted in source coverage", reason: "Credibility on outbreak trial mechanics" }
  internal_links: []
  visual_brief: "Map graphic of DRC outbreak region; avoid alarmist imagery"
  seo:
    primary_keyword: "Ebola vaccine trial 2026"
    supporting_keywords: ["DRC Ebola outbreak", "new Ebola vaccine candidates", "Ebola trial WHO"]
    format: "News explainer, 700–900 words"
    schema_markup: "NewsArticle"
    cluster: "infectious disease / outbreak preparedness"
  discover_notes: "Strong AI-citation candidate: specific entity, primary WHO source, natural question format"
  key_takeaways:
    - "Trial expansion ≠ approval"
    - "No direct US risk currently indicated"
  estimated_word_count: "700-900"
execution_notes: "Fast-turn explainer; keep tone calm, avoid outbreak-panic framing"
confidence: high
```

### P2 — Potassium Salt Substitute Study (Full Brief)

```yaml
brief:
  primary_headline: "A New Global Study Says Swapping Your Salt Could Save Millions of Lives — Should You?"
  alternate_headlines:
    - "Potassium Salt vs. Regular Salt: What a New Global Health Study Found"
    - "Is Potassium-Enriched Salt the Easiest Heart-Health Swap You're Not Making?"
  topic: "Potassium-enriched salt substitute global health outcomes study"
  primary_entity: "Potassium-enriched salt substitute"
  search_intent: "Evaluative — 'is this worth doing,' 'does salt substitute work'"
  angle: "Take a population-level global modeling study and translate it into an individual, practical decision — what it would mean to switch, caveats on who shouldn't (e.g., kidney disease patients)."
  why_now: "Published directly in Nature (11/04) with a traceable DOI — the strongest primary source in today's cycle; connects to persistent consumer interest in sodium/heart health."
  integrity_flags:
    - "⚠️ Integrity note: Confirm whether this is modeled/epidemiological projection vs. interventional trial data — do not overstate as individually RCT-proven."
    - "⚠️ Integrity note: Potassium substitutes carry real contraindications (kidney disease, certain medications) — must be flagged prominently, not buried."
  outline:
    intro: "The swap: what potassium-enriched salt is and why researchers modeled it globally"
    sections:
      - "What the study actually measured (population health outcomes, not individual trial)"
      - "Who should NOT make this switch (kidney disease, ACE inhibitors, etc.)"
      - "How to actually try it if appropriate"
    conclusion: "Bottom line: a low-cost intervention with real caveats"
  key_data_points:
    - "Global modeling study on sodium chloride → potassium-enriched salt substitution, published Nature, 11/04"
  source_plan:
    - { publisher: "Nature", url: "https://www.nature.com/articles/s44360-026-00216-9", tier: 1, used_for: "Primary study data" }
  evidence_requirements: "Moderate — pull specific risk-reduction figures from the study before drafting; needs_expert_validation for contraindication framing"
  expert_sources:
    - { type: "Registered Dietitian Nutritionist or Cardiologist", name: "Source via AHA or Academy of Nutrition and Dietetics commentary", reason: "Needed to responsibly caveat kidney/medication contraindications" }
  internal_links: []
  visual_brief: "Simple before/after salt-shaker graphic; avoid overpromising 'miracle swap' framing"
  seo:
    primary_keyword: "potassium salt substitute health benefits"
    supporting_keywords: ["sodium reduction heart health", "potassium chloride salt substitute risks", "low sodium diet swap"]
    format: "Evaluative explainer, 900–1100 words"
    schema_markup: "NewsArticle / HealthTopicContent"
    cluster: "nutrition and diet science / cardiovascular health"
  discover_notes: "High AI-citation potential: specific entity, DOI-traceable, durable, natural question fit ('does potassium salt substitute reduce heart disease risk')"
  key_takeaways:
    - "Population-level modeling, not an individual guarantee"
    - "Contraindicated for kidney disease and certain medications — consult a doctor first"
  estimated_word_count: "900-1100"
execution_notes: "Require expert quote on contraindications before publishing — do not run as pure data recap"
confidence: medium
```

### P3 — Stanford Alzheimer's Study (Concise Brief)

```yaml
brief:
  headline: "Can a Brain Scan Predict Alzheimer's Before Symptoms Start? What a New Stanford Study Found"
  topic: "Stanford study: brain activity patterns may predict Alzheimer's years before memory loss"
  angle: "Skeptical/evaluative — explain the finding's real scope without overstating diagnostic certainty on an emotionally sensitive topic"
  key_data_points:
    - "Stanford Medicine study (11/04) on brain activity patterns and Alzheimer's prediction"
  integrity_flags:
    - "⚠️ Single-source institutional report — confirm cohort size, study design (observational vs. longitudinal), and peer-review status"
    - "⚠️ Avoid implying this is a diagnostic test available today"
  expert_type_needed: "Neuropsychologist or geriatrician to contextualize clinical applicability"
  seo:
    primary_keyword: "brain activity Alzheimer's prediction study"
    format: "Concise news explainer, 500–650 words"
    serp_difficulty: Medium
  sources:
    - { publisher: "Stanford Medicine", url: "https://med.stanford.edu/news/all-news/2026/11/alzheimers-brain-activity.html" }
  estimated_word_count: "500-650"
```

---

## 7. Rejected Topics Log (selected, non-exhaustive — see §2 for cluster-level accounting)

| Topic | Reason |
|---|---|
| Cannabis use linked to cardiovascular risk | 02b reject — unverifiable, single secondary aggregator (News-Medical), no primary source named |
| First Medicare ExRad study (CT radiation variation) | 02b reject — same unverifiable-secondary-source issue |
| Compounded eye drops recall (leaching chemical / GLP-1 mix-up) | 02b reject — single source, no FDA.gov notice, breaking-recall exception not met |
| Olmesartan BP medication recall (continued coverage) | Existing — covered 11/03, no new development |
| Flour/cinnamon recall (continued coverage) | Existing — covered 11/01 |
| FDA Tractor Wheels choking recall (continued coverage) | Existing — covered 11/01 |
| Impella heart pump recall (continued coverage) | Existing — covered 11/01 |
| Men's Mental Health Month | Existing — covered 11/02; flagged recurring (3+ runs) |
| Daylight Saving Time circadian/cardiovascular effects | Existing — covered 10/31 |
| Outside Magazine "wellness trends do more harm" | Existing — duplicates 11/04 skeptical roundup |
| Aflac "Wellness Paradox" survey | Brand safety — single-source corporate PR, commercial conflict of interest |
| CVS Health pharmacy/insurance split | Off-category — pure business news, no patient-access angle |
| Clinical trial industry/vendor cluster (Signant Health, Walmart/Care Access, AJMC costs, Brazil/Canada regulatory) | Off-category — trade/industry news, not consumer health |
| Pfizer pediatric trial lower doses (5–11yo) | Rejected — unclear/possibly stale recycled article ID |
| Mitch McConnell / Chris Murphy health searches | Off-category — political figure health speculation |
| "Dairy vs vegan milk nutrition study" / "FDA infant formula updates" (Trends-only) | Weak signal — rising query with no corroborating News article |
| Local/institutional wellness PR (school wellness centers, college wellness days, benefits fairs, McKinsey market sizing, GMA generic wellness page) | Off-category — local/too narrow or non-editorial market research |

---

## 8. Integrity Flags — Consolidated

- ⚠️ **Ebola vaccine trial:** Clarify trial-stage status, not approval; avoid implying outbreak resolution or US risk.
- ⚠️ **Potassium salt study:** Confirm modeled/epidemiological nature vs. interventional trial; contraindications (kidney disease, ACE inhibitors/potassium-sparing medications) must be prominent, not buried.
- ⚠️ **Alzheimer's biomarker study:** Single-source, confirm study design and cohort size before publishing; avoid implying diagnostic availability.

---

## 9. Run Notes

- `site_url` not configured — self-check skipped for all candidates; competitor-list fallback (configs/competitor_list.yaml) used to inform SERP-gap judgments.
- Today's Google News Radar was dominated by duplicate coverage of the past week's recalls and wellness-skepticism pieces, plus a large volume of local/institutional PR and clinical-trial industry trade news — none of which met category or audience-fit thresholds. This is reflected in a thin retained list (3 candidates + 1 monitor) consistent with "default is no."
- Two Skill 02b rejections (cannabis study, CT radiation study) both failed for the identical reason — reliance on News-Medical as the sole source without confirmed primary traceability. Worth flagging upstream: News-Medical should not be treated as a trusted secondary source for health-claim verification absent independent corroboration.
- Men's Mental Health Month and wellness-trends-skepticism are now recurring themes across 3+ consecutive runs — recommend deprioritizing further coverage unless new data emerges.
- Run archived to `data/run_history.yaml`; dashboard written to `outputs/daily_newsroom_dashboard/2026-11-05.html`.